vs
CANTALOUPE, INC.（CTLP）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
CANTALOUPE, INC.的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$78.7M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs -0.1%，领先384.1%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 6.8%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 7.7%）
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CTLP vs RIGL — 直观对比
营收规模更大
CTLP
是对方的1.1倍
$69.8M
营收增速更快
RIGL
高出14.4%
6.8%
净利率更高
RIGL
高出384.1%
-0.1%
两年增速更快
RIGL
近两年复合增速
7.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $78.7M | $69.8M |
| 净利润 | $-70.0K | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 2.0% | 33.2% |
| 净利率 | -0.1% | 384.0% |
| 营收同比 | 6.8% | 21.2% |
| 净利润同比 | -101.4% | 1769.2% |
| 每股收益（稀释后） | $0.00 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTLPRIGL
| Q4 25 | $78.7M | $69.8M | ||
| Q3 25 | $80.9M | $69.5M | ||
| Q2 25 | $82.6M | $101.7M | ||
| Q1 25 | $75.4M | $53.3M | ||
| Q4 24 | $73.7M | $57.6M | ||
| Q3 24 | $70.8M | $55.3M | ||
| Q2 24 | $72.7M | $36.8M | ||
| Q1 24 | $67.9M | $29.5M |
净利润CTLPRIGL
| Q4 25 | $-70.0K | $268.1M | ||
| Q3 25 | $-919.0K | $27.9M | ||
| Q2 25 | $6.8M | $59.6M | ||
| Q1 25 | $49.2M | $11.4M | ||
| Q4 24 | $5.0M | $14.3M | ||
| Q3 24 | $3.6M | $12.4M | ||
| Q2 24 | $2.2M | $-1.0M | ||
| Q1 24 | $4.7M | $-8.2M |
毛利率CTLPRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | 39.6% | 93.1% |
营业利润率CTLPRIGL
| Q4 25 | 2.0% | 33.2% | ||
| Q3 25 | 2.0% | 40.9% | ||
| Q2 25 | 6.3% | 60.1% | ||
| Q1 25 | 9.1% | 23.9% | ||
| Q4 24 | 8.4% | 28.9% | ||
| Q3 24 | 5.8% | 25.4% | ||
| Q2 24 | 4.9% | 1.2% | ||
| Q1 24 | 6.3% | -23.6% |
净利率CTLPRIGL
| Q4 25 | -0.1% | 384.0% | ||
| Q3 25 | -1.1% | 40.2% | ||
| Q2 25 | 8.3% | 58.6% | ||
| Q1 25 | 65.2% | 21.5% | ||
| Q4 24 | 6.7% | 24.9% | ||
| Q3 24 | 5.0% | 22.5% | ||
| Q2 24 | 3.0% | -2.8% | ||
| Q1 24 | 6.9% | -27.9% |
每股收益（稀释后）CTLPRIGL
| Q4 25 | $0.00 | $14.11 | ||
| Q3 25 | $-0.02 | $1.46 | ||
| Q2 25 | $0.10 | $3.28 | ||
| Q1 25 | $0.65 | $0.63 | ||
| Q4 24 | $0.07 | $0.82 | ||
| Q3 24 | $0.04 | $0.70 | ||
| Q2 24 | $0.03 | $-0.06 | ||
| Q1 24 | $0.06 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.0M | $155.0M |
| 总债务越低越好 | $37.7M | $52.5M |
| 股东权益账面价值 | $252.5M | $391.5M |
| 总资产 | $381.9M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CTLPRIGL
| Q4 25 | $53.0M | $155.0M | ||
| Q3 25 | $55.0M | $137.1M | ||
| Q2 25 | $51.1M | $108.4M | ||
| Q1 25 | $46.3M | $77.1M | ||
| Q4 24 | $27.7M | $77.3M | ||
| Q3 24 | $33.1M | $61.1M | ||
| Q2 24 | $58.9M | $49.1M | ||
| Q1 24 | $50.2M | $49.5M |
总债务CTLPRIGL
| Q4 25 | $37.7M | $52.5M | ||
| Q3 25 | $38.3M | $60.0M | ||
| Q2 25 | $38.7M | $60.0M | ||
| Q1 25 | $39.2M | $60.0M | ||
| Q4 24 | $37.0M | $60.0M | ||
| Q3 24 | $37.3M | $60.0M | ||
| Q2 24 | $37.5M | $60.0M | ||
| Q1 24 | $38.1M | $60.0M |
股东权益CTLPRIGL
| Q4 25 | $252.5M | $391.5M | ||
| Q3 25 | $251.8M | $117.6M | ||
| Q2 25 | $251.0M | $81.9M | ||
| Q1 25 | $240.7M | $18.6M | ||
| Q4 24 | $190.1M | $3.3M | ||
| Q3 24 | $186.2M | $-14.6M | ||
| Q2 24 | $181.7M | $-29.9M | ||
| Q1 24 | $178.8M | $-31.7M |
总资产CTLPRIGL
| Q4 25 | $381.9M | $513.6M | ||
| Q3 25 | $389.5M | $242.5M | ||
| Q2 25 | $381.9M | $206.7M | ||
| Q1 25 | $370.5M | $176.0M | ||
| Q4 24 | $303.0M | $164.0M | ||
| Q3 24 | $312.1M | $139.4M | ||
| Q2 24 | $335.6M | $128.4M | ||
| Q1 24 | $319.9M | $126.5M |
负债/权益比CTLPRIGL
| Q4 25 | 0.15× | 0.13× | ||
| Q3 25 | 0.15× | 0.51× | ||
| Q2 25 | 0.15× | 0.73× | ||
| Q1 25 | 0.16× | 3.23× | ||
| Q4 24 | 0.19× | 18.25× | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-614.0K | — |
| 自由现金流率自由现金流/营收 | -0.8% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $25.8M | — |
8季度趋势，按日历期对齐
经营现金流CTLPRIGL
| Q4 25 | $3.1M | $22.0M | ||
| Q3 25 | $7.0M | $24.0M | ||
| Q2 25 | $9.4M | $30.5M | ||
| Q1 25 | $22.4M | $-893.0K | ||
| Q4 24 | $522.0K | $14.5M | ||
| Q3 24 | $-12.0M | $21.7M | ||
| Q2 24 | $14.3M | $302.0K | ||
| Q1 24 | $14.7M | $-5.0M |
自由现金流CTLPRIGL
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $3.5M | — | ||
| Q2 25 | $4.3M | — | ||
| Q1 25 | $18.6M | — | ||
| Q4 24 | $-3.8M | — | ||
| Q3 24 | $-15.8M | — | ||
| Q2 24 | $8.5M | — | ||
| Q1 24 | $11.4M | — |
自由现金流率CTLPRIGL
| Q4 25 | -0.8% | — | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 5.3% | — | ||
| Q1 25 | 24.6% | — | ||
| Q4 24 | -5.1% | — | ||
| Q3 24 | -22.3% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.9% | — |
资本支出强度CTLPRIGL
| Q4 25 | 4.8% | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 5.8% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 7.9% | — | ||
| Q1 24 | 4.8% | — |
现金转化率CTLPRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | 1.38× | 0.51× | ||
| Q1 25 | 0.46× | -0.08× | ||
| Q4 24 | 0.10× | 1.01× | ||
| Q3 24 | -3.36× | 1.75× | ||
| Q2 24 | 6.47× | — | ||
| Q1 24 | 3.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
RIGL
暂无分部数据
